Table 3.
Sensitivity comparisons of two commercial SARS-CoV-2 rapid antigen tests on B.1.1.7 samples vs samples from April and September 2020
|
Innova |
SureScreen-V |
|||||
|---|---|---|---|---|---|---|
| Number of samples | Sensitivity vs RT-rtPCR (95% CI) | p value* | Number of samples | Sensitivity vs RT-rtPCR (95% CI) | p value* | |
| B.1.1.7 | ||||||
| Overall | 23 | 78·3% (58·1–90·3) | .. | 23 | 65·2% (44·9–81·2) | .. |
| N Ct value <25 | 16 | 100·0% (80·6–100) | .. | 16 | 87·5% (64·0–97·8) | .. |
| April, 2020 | ||||||
| Overall | 23 | 82·6% (62·9–93·0) | 1·0 | 23 | 60·9% (40·8–77·8) | 1·0 |
| N Ct value <25 | 16 | 100·0% (80·6–100) | 1·0 | 16 | 81·2% (57·0–93·4) | 1·0 |
| September, 2020 | ||||||
| Overall | 23 | 82·6% (62·9–93·0) | 1·0 | 23 | 73·9% (53·5–87·4) | 0·75 |
| N Ct value <25 | 16 | 100·0% (80·6–100·0) | 1·0 | 16 | 100·0% (80·6–100·0) | 0·48 |
RT-rtPCR=quantitative RT-PCR. N=SARS-CoV-2 nucleocapsid. Ct=cycle threshold. SureScreen-V=SureScreen visual.
*
Two-tailed p values were determined for the comparison of sensitivities between the B.1.1.7 samples (December, 2020, and January, 2021) and earlier samples (assumed to be non-B.1.1.7) with Fischer's exact test.